



UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ

---

**FACULTAD DE CIENCIAS QUÍMICAS**

**PROGRAMA DE POSGRADO EN BIOPROCESOS**

**ALIMENTO FUNCIONAL: AGENTES  
CO-MICROENCAPSULANTES EN LA  
CONSERVACIÓN DE QUERCETINA 3-D-  
GALACTOSIDE-BACILLUS CLAUSII**

**TESIS QUE PARA OBTENER EL GRADO DE  
MAESTRO EN CIENCIAS EN BIOPROCESOS**

**PRESENTA:**

**L. N. Héctor Alfonso Enciso Huerta**

**DIRECTOR DE TESIS:  
DRA. María Zenaida Saavedra Leos**

**CO-DIRECTOR DE TESIS:**

**DR. Miguel Ángel Ruiz Cabrera**

**DRA. Claudia Álvarez Salas**

---

SAN LUIS POTOSÍ, S. L. P.

Agosto 2022



UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ

---

## FACULTAD DE CIENCIAS QUÍMICAS

### PROGRAMA DE POSGRADO EN BIOPROCESOS

# ALIMENTO FUNCIONAL: AGENTES CO-MICROENCAPSULANTES EN LA CONSERVACIÓN DE QUERCETINA 3-D-GALACTOSIDE-BACILLUS CLAUSII

TESIS UE PARA OBTENER EL GRADO DE:

**MAESTRO EN CIENCIAS EN BIOPROCESOS**

**PRESENTA:**

**L. N. Héctor Alfonso Enciso Huerta**

**DIRECTOR DE TESIS:**

**DRA. María Zenaida Saavedra Leos**

**CO-DIRECTOR DE TESIS:**

**DR. Miguel Ángel Ruiz Cabrera**

**SINODALES:**

**PRESIDENTE:**

**DRA. María Zenaida Saavedra Leos** \_\_\_\_\_

**SECRETARIO:**

**DR. Miguel Ángel Ruiz Cabrera** \_\_\_\_\_

**VOCAL:**

**DRA. Claudia Álvarez Salas** \_\_\_\_\_

San Luis Potosí, S.L.P.  
Julio 11, 2022

**Comité Académico del Posgrado  
En Ciencias en bioprocesos  
Facultad de Ciencias Químicas / UASLP  
Presente.\_**

Por medio de la presente comunicamos que la tesis llevada a cabo por el alumno de Maestría L.N. Héctor Alfonso Enciso Huerta, titulada “Alimento funcional: agentes co-microencapsulantes en la conservación de queracetina 3-D-Galactoside-*Bacillus calusii*”, ha sido concluida y aprobada por el comité tutorial para dar inicio a los trámites correspondientes para su titulación, la cual tendrá lugar el próximo día **12 de agosto** a las **12:00** hrs. en el Auditorio Chico (G203), de la Facultad.

ATENTAMENTE

Dra. María Zenaida Saavedra Leos \_\_\_\_\_  
Directora de Tesis

Dr. Miguel Ángel Ruiz Cabrera \_\_\_\_\_  
Co-Director

Dra. Claudia Álvarez Salas \_\_\_\_\_  
Asesora

**Proyecto realizado en:**

Laboratorio de ingeniería de alimentos de la Facultad de Ciencias Químicas de la  
Universidad Autónoma de San Luis Potosí

**Con financiamiento de:**

Consejo Nacional de Ciencia y Tecnología (CONACYT), mediante el proyecto  
No. 784106.

El programa de Maestría en Ciencias en Bioprocessos de la Universidad Autónoma  
de San Luis Potosí pertenece al Programa Nacional de Posgrados de Calidad  
(PNPC) del CONACYT, registro 000588, en el Nivel Maestría (Consolidado).

Número de registro de la beca otorgada por CONACYT: 784106

CVU:1077957



Alimento funcional: agentes co-microencapsulantes en la conservación de  
queracetina 3-d-galactoside-bacillus clausii por Héctor Alfonso Enciso Huerta se  
distribuye bajo una [Licencia Creative Commons Atribución-NoComercial-SinDerivadas 4.0 Internacional](#).

## **AGRADECIMIENTOS ACADÉMICOS**

A mi comité tutorial, la Dra. María Zenaida Saavedra Leos, el Dr. Miguel Ángel Ruiz Cabrera y la Dra. Claudia Álvarez Salas, por permitirme formar parte de este proyecto, por la paciencia y dedicación con la que realizaron su trabajo y me brindaron su apoyo durante estos dos años.

Agradezco de igual manera al Dr. Fidel Martínez Gutierrez y a la Dra. Avelina Franco Vega, por compartir sus conocimientos y experiencia para enriquecer este trabajo, así como al personal de los laboratorios de ingeniería de alimentos y de microbiología clínica, por la amabilidad con la que me recibieron

## **Contenido**

<b>Abstract</b> .....	1
<b>Abstract traducido al español</b> .....	2
<b>Resumen</b> .....	3
<b>Introducción</b> .....	3
<b>Objetivos</b> .....	6
<b>Materiales y métodos</b> .....	6
1.1 Materiales.....	6
1.2 Preparación de liofilizados.....	7
1.3 Determinación de la viabilidad.....	7
1.4 Actividad antioxidante (AA).....	8
<b>Resultados y discusión</b> .....	10
<b>Conclusiones</b> .....	13
<b>Bibliografía</b> .....	14
<b>Reseña del artículo: Evaluation of two active system encapsulants matrices with quercetin and Bacillus clausii for functional foods</b> .....	16
<b>ANEXO: MANUSCRITO ENVIADO</b> .....	17

## **Abstract**

Currently, the demand for functional foods has been increasing in the public interest to improve their life expectations and general health. Food matrices containing probiotic microorganisms and active compounds encapsulated into carrier agents are essential in this context. Encapsulation by the lyophilization method is widely used because oxidation reactions affecting physicochemical and nutritional food properties are usually avoided. Encapsulated functional ingredients such as quercetin and *Bacillus clausii* using two carrier agents' matrices performed in I [inulin (I); lactose (L) and maltodextrin (MX)] and II [(Arabic (A), Guar (G) and Xanthan (X) Rubbers)] are presented in this work. A D-optimal procedure involving 59 experiments was designed to evaluate each matrix's yield, viability, and antioxidant activity (AA). Matrix I (33.3 I; 33.3 L; 33.3 MX) and matrix II (33.3 A; 33.3 G; 33.3 X) exhibited the best yield.

Keywords: functional, food, Inulin, Lactose

### **Abstract traducido al español**

Actualmente, la demanda de alimentos funcionales ha aumentado gracias al interés del público por incrementar su expectativa de vida y mejorar su salud en general. En este contexto, son esenciales las matrices alimentarias que contengan microorganismos probióticos y compuestos activos encapsulados dentro de agentes acarreadores. La encapsulación por el método de liofilización es ampliamente utilizada debido a que usualmente se evitan las reacciones de oxidación que afectan las propiedades fisicoquímicas y nutricionales de los alimentos. En este trabajo, se presentan ingredientes funcionales encapsulados como la quercetina y el *Bacillus clausii*, con la utilización de dos matrices de agentes acarreadores formadas por: I (inulina (I); lactosa (L) y maltodextrina (MX)) y II (goma arábica (A); goma guar (G) y goma xantana (X)). Mediante un diseño D-optimal, se condujeron 59 experimentos en los que se evaluó el rendimiento, viabilidad y actividad antioxidante (AA). La matriz I (1/3 I; 1/3 L; 1/3 MX) y la matriz II (1/3 A; 1/3 G; 1/3 X), exhibieron el mejor rendimiento.

Palabras clave: funcional, alimento, inulina, lactosa

## **Resumen**

Evaluation of two active system encapsulants matrices with quercetin and  
3 Bacillus clausii for functional lyophilized foods preparation

## **Introducción**

Según el Codex alimentario (Commission, 2007) un alimento es toda sustancia elaborada, semielaborada o en bruto, que se destina al consumo humano (CXS 1-1985) que tiene un aporte nutricional. En los últimos años, derivado de la pandemia mundial del virus SARS-CoV-2 (COVID-19) la Organización Mundial de la salud (OMS) indicó consumir alimentos saludables, ya que, si bien no puede prevenir ni curar la enfermedad, es fundamental para el buen funcionamiento del sistema inmunológico y se reduce considerablemente la probabilidad de aparición de otras enfermedades como obesidad, diabetes, enfermedades cardíacas y algunos tipos de cáncer. Por lo anterior se considera que la alimentación juega un papel preponderante en la prevención de estas afecciones que tienen un impacto a nivel de salud pública. Aunado a lo anterior, un “alimento funcional”, se define según la guía (European society for clinical nutrition and metabolism) ESPEN como un alimento fortificado con ingredientes, nutrientes o componentes adicionales, con la intención de manifestar beneficios específicos para la salud. Debido a lo anterior la producción de alimentos funcionales, se ha convertido en la última década en una de las industrias biotecnológicas de alimentos más importantes, dada la creciente demanda por parte de los consumidores al buscar alargar su expectativa de vida y mejorar su salud en general, debido a la concientización sobre la prevención de enfermedades como la diabetes, el cáncer y el alzheimer. (Sarao & Arora, 2017). Comúnmente, los antioxidantes son compuestos presentes dentro de los alimentos funcionales, estos son agregados a los productos solos o en combinación con otros compuestos que permitan un sinergismo, como el que ocurre entre la vitamina C al regenerar al radical tocoferilo de la vitamina E tras su oxidación. (Addor, 2017). Los antioxidantes se añaden a los alimentos con la intención de obtener diferentes beneficios como el de suprimir la oxidación lipídica para aumentar la vida de anaquel de los productos, así como el reducir las concentraciones de radicales

libres dentro del organismo, mejorando la salud del consumidor, (Ciriminna et al., 2017). La quercetina es un antioxidante flavonoide, encontrado en manzanas, uvas, frijoles, brócoli, cebollas rojas, tomates, semillas oleaginosas, flores, hojas de té y en el Ginko biloba. La ingesta diaria en la dieta de quercetina es de entre 10 y 16 mg al día, sin embargo la concentración recomendada de quercetina en un suplemento debe ser de 1g por día (Khan et al., 2020). Entre los mecanismos por los cuales la quercetina ejerce un efecto benéfico contra las enfermedades, se encuentran: En el asma alérgica, la quercetina inhibe la expresión del gen MUC5AC en las células NCI-H292, lo cual repercute a nivel ciliar en la mucosa nasal humana, siendo un agente antisecretor, inhibiendo la secreción mucosa de las células epiteliales, mientras mantiene un movimiento ciliar normal. (Jafarinia et al., 2020). Marunaka et al. (2017) demostraron que la ingesta oral de entre 150 a 730 mg/día durante cuatro semanas de quercetina, tiene un efecto antihipertensivo, reduciendo la presión sistólica y diastólica en pacientes en la primera etapa de la hipertensión. Por otra parte, se ha observado que en pacientes con síndrome metabólico, la ingesta de 150 mg/día de quercetina durante cinco semanas, reduce significativamente la presión sistólica. Un estudio in vitro, elaborado Reyes-Farias & Carrasco-Pozo. (2019) indicó que la quercetina ha funcionado como agente antiviral contra el VIH, inhibiendo enzimas como la integrasa, la proteasa y la transcriptasa inversa, reduciendo significativamente la replicación del virus del VIH. Otro tipo de compuestos activos en los alimentos funcionales son los probióticos, estos confieren beneficios a la salud, mediante diferentes mecanismos como la producción de enzimas biliares, ácidos orgánicos, hormonas de saciedad, la modulación del sistema inmune mediante el aumento en la respuesta de los anticuerpos, la competencia por sustratos contra organismos patógenos y la interacción con la microbiota. (Sanders et al., 2019). *Bacillus clausii* es una bacteria aeróbica, gram-positiva utilizada como probiótico, tiene la capacidad de formar esporas y colonizar el intestino, (Paparo et al., 2020). *B. clausii* también es resistente a factores como el calor, el pH gástrico y los antibióticos, puede tolerar medios alcalinos, sus condiciones óptimas de crecimiento son a 40°C y a un pH de 9,0. (De Castro et al., 2019). Autores como De Castro et al. (2019). han reportado la utilización del *B. clausii* durante 7 días, para el tratamiento de la diarrea aguda

infantil, viral y asociada al uso de antibióticos, donde se logró una reducción en el tiempo de la enfermedad, los síntomas gastrointestinales y la frecuencia de evacuaciones. Recientemente en 2020, (Plomer et al., 2020), utilizaron al *B. clausii* para aminorar los efectos adversos del tratamiento para eliminar a la Helicobacter pylori, en donde por lo general se administran antibióticos que causan náusea, inflamación, vómito y diarreas, haciendo que se opte por terminar la administración del medicamento, dando como resultado el riesgo de hacer que el tratamiento falle y la Helicobacter pylori cree resistencia a los antibióticos.

Con la finalidad de mantener la actividad antioxidante y viabilidad de los productos probióticos se utilizan técnicas de microencapsulación, de cualquier ingrediente activo que se busque añadir a un alimento, son protegidos de factores ambientales como el calor, el oxígeno y la humedad. (Zuidam & Nedović, 2010). Entre las técnicas de secado más empleadas para la producción de alimentos probióticos, se encuentran el secado por aspersión y la liofilización, este último permite preservar no sólo las cualidades nutricionales de los alimentos, sino también sus aromas y sabores, además de poder ser rehidratados tras el proceso, gracias a la porosidad del producto final. (Muñoz-López et al., 2018). La liofilización es ampliamente utilizada en la industria de alimentos, debido a que, a diferencia de los procesos de secado con calor, esta no cataliza reacciones de oxidación que afectan las propiedades fisicoquímicas y nutricionales de los alimentos. (Caballero et al., 2017). El secado por liofilización utiliza la sublimación y puede ser utilizado para la encapsulación de aromas, esencias, fármacos y cualquier material termosensible en general. Tomando en consideración la importancia de los antioxidantes y probióticos en la salud, en esta investigación se planteó obtener un ingrediente funcional que contenga *B. clausii* y quercetina microencapsulado por liofilización.

## **Objetivos**

### **Objetivo general**

- Elaborar y caracterizar un ingrediente funcional microencapsulado de *B. clausii*/quercetina mediante liofilización.

### **Objetivos específicos**

- Evaluar el efecto de inulina, lactosa y maltodextrina, sobre el rendimiento, la viabilidad de *B. clausii* y la actividad antioxidante de la quercetina.
- Evaluar el efecto de la goma arábiga, xantana y guar sobre el rendimiento, la viabilidad de *B. clausii* y la actividad antioxidante de la quercetina.
- Evaluar el efecto sinérgico de agentes acarreadores y gomas sobre el rendimiento, la viabilidad de *B. clausii* y la actividad antioxidante de la quercetina.

## **Materiales y métodos**

### **1.1 Materiales**

Maltodextrina (MX) comercial de almidón de maíz de INGREDION México (Guadalajara, México). Con equivalentes de dextrosa (DE) de 10, peso molecular de 1625 g/mol y un grado de polimerización (DP) de 2-16 unidades de glucosa. Inulina (IN) obtenida de INGREDION Mexico (Guadalajara, Mexico). α-Lactosa monohidratada (L), ( $\text{La}\cdot\text{H}_2\text{O}$ , pureza  $\geq 99,9 \%$ ) adquirida de Sigma Aldrich Chemical Co., Metanol, (MeOH, pureza  $\geq 99,8 \%$ ) de J.T. Baker. Gomas Arábiga (A), Guar (G) y Xantana (X) de INGREDION México (Guadalajara, México). Cepas de (*B. clausii*) en solución de sinuberase fue obtenido de Sanofi-Aventis México, S.A. de C.V. (Coyoacán, Ciudad de México, México). Quercetina 3-D-Galactósido (pureza  $\geq 99\%$ ) adquirida de Química Farmacéutica Esteroidal S.A de C.V., (Tláhuac, Ciudad de México, México). Agar tripticasa de soya adquirido de Dickinson de México S.A de C.V. (Ciudad de México, México) y 2,2-difenil-1-picrilhidracilo (DPPH) grado analítico de Sigma–Aldrich Chemical Co

## 1.2 Preparación de liofilizados

Con base al diseño de experimentos, se prepararon 100g de muestras p/p, con 10 g de la matriz I elaborada con I, L y MX y 1g de matriz II formada por A, G y X. Cada fracción de masa para la matriz I y II fue establecida de acuerdo con el diseño de experimentos. Los componentes de cada matriz se pasaron por un tamiz de 1mm y se añadieron 87 g de agua desionizada, seguida de agitación magnética a 35°C por 5 minutos.

Se añadió 1g de quercetina y 1g de solución de *B. clausii* a la mezcla para obtener un volumen final de la solución de 100g (p/p). Las muestras fueron almacenadas en oscuridad a -80 °C. El proceso de microencapsulación se llevó a cabo por sublimación en un liofilizador (IIShinbiobase® Modelo TFD8501, Gyeonggi-do, Corea del sur ) con una presión de vacío de 5 mTorr a -65 °C por aproximadamente 120h.

## 1.3 Determinación de la viabilidad

Se determinó la viabilidad de *B. clausii* antes y después del proceso de encapsulación, suspendiendo 1g de micropartículas obtenidas en 9 ml de solución salina (NaCl, 0.9% p/v). Con la finalidad de romper las microcápsulas, la suspensión se agitó durante 10 minutos en un vortex y calentado a baño maría por 10 minutos a 50 °C. Las células viables se analizaron de acuerdo con el método descrito por (Miles et al., 1938). Brevemente, se realizaron diluciones desde 1x10-3 a 1x10-9 en solución salina y se sembraron en agar tripticasa de soya, posteriormente se incubaron a 35 °C por 24 h. La evaluación se realizó por triplicado y se reporta como unidades formadoras de colonia por gramo (CFU/g), usando la ecuación 1

$$\frac{UFC}{g} = \left[ \frac{N^{\circ} \text{ de colonias en caja} * \text{factor de dilución}}{mL \text{ de muestra sembrada}} \right] (1)$$

#### 1.4 Actividad antioxidante (AA)

La actividad antioxidante de la quercetina se determinó mediante el método descrito por (Brand-Williams et al., 1995). Brevemente, 1.7 mL de solución alcohólica de DPPH (0,1 mmol DPPH/L) se mezcló con 1.7 mL de suspensión del microencapsulado, donde las concentraciones del microencapsulado fueron de 2,5, 5 y 15 µg/mL. La mezcla se dejó en oscuridad por 30 minutos y se midió la absorbancia a 537 nm usando un espectrofotómetro UV-Vis Evolution 220 (Thermo Scientific, Walthman, MA. USA). El porcentaje de actividad antioxidante se calculó usando la ecuación 2:

$$\text{Actividad antioxidante}(\%DPPH) = \frac{A_0 - A_{30}}{A_0} \times 100 \quad (2)$$

Donde  $A_0$  representa la absorbancia de la solución blanco (DPPH y etanol sin microencapsulado),  $A_{30}$  representa la absorbancia de la solución de DPPH y etanol con microcápsulas después de 30 minutos. La actividad antioxidante se determinó por triplicado para cada muestra.

#### 1.5 Diseño de experimentos y análisis estadístico

Se evaluaron dos mezclas independientes: Matriz I, consistía en inulina (IN), lactosa (L) y maltodextrina (MX), mientras que la Matriz II consistía en las gomas Arábiga (A), guar (G) y xantana (X). Los niveles superior e inferior de estas variables estuvieron entre 0 y 100 (%p), y la suma de componentes en cada mezcla fue de 100% para cada prueba. Las variables de respuesta fueron rendimiento (%), Bc ( $\text{Log}_{10}$  CFU/g), y actividad antioxidante (con DPPH a concentraciones de 5, 10, y 30 µg/g)). De esta manera, un diseño de experimentos combinado con dos matrices para un modelo especial cúbico x especial cúbico, fue seleccionado para evaluar el efecto de cada factor sobre las variables de respuesta. La tabla 1 muestra los resultados de 59 ensayos realizados en el laboratorio en orden aleatorio.

Se llevó a cabo un análisis de varianza (ANOVA), para cada variable de respuesta (Rendimiento, Bc y actividad antioxidante), usado el software Design-Expert® versión 12 (versión de prueba) a un nivel de significancia de 0.05. El modelo Scheffe analizado, especial cúbico x especial cúbico se muestra en la ecuación 3:

$$Y = (\alpha_1A + \alpha_2B + \alpha_3C + \alpha_4AB + \alpha_5AC + \alpha_6BC + \alpha_7ABC) \times (\kappa_1D + \kappa_2E + \kappa_3F + \kappa_4DE + \kappa_5DF + \kappa_6EF + \kappa_7DEF) \quad (3)$$

Que es una forma expandida que da como resultado 49 parámetros ajustables.

Tabla 1. Diseño experimental de dos matrices para un modelo especial cúbico x especial cúbico.

No	Run	Matrix I			Matrix II		
		IN	L	MX	A	G	X
1	44	100.0	0.0	0.0	0.0	50.0	50.0
2	15	0.0	100.0	0.0	100.0	0.0	0.0
3	51	0.0	100.0	0.0	0.0	100.0	0.0
4	3	0.0	100.0	0.0	0.0	0.0	100.0
5	20	0.0	100.0	0.0	50.0	50.0	0.0
6	57	0.0	100.0	0.0	50.0	0.0	50.0
7	48	0.0	100.0	0.0	0.0	50.0	50.0
8	32	0.0	0.0	100.0	100.0	0.0	0.0
9	35	0.0	0.0	100.0	0.0	100.0	0.0
10	41	0.0	0.0	100.0	0.0	0.0	100.0
11	11	0.0	0.0	100.0	50.0	50.0	0.0
12	18	0.0	0.0	100.0	50.0	0.0	50.0
13	39	0.0	0.0	100.0	0.0	50.0	50.0
14	25	50.0	50.0	0.0	100.0	0.0	0.0
15	43	50.0	50.0	0.0	0.0	100.0	0.0
16	47	50.0	50.0	0.0	0.0	0.0	100.0
17	8	50.0	50.0	0.0	50.0	50.0	0.0
18	40	50.0	50.0	0.0	50.0	0.0	50.0
19	27	50.0	50.0	0.0	0.0	50.0	50.0
20	19	50.0	0.0	50.0	100.0	0.0	0.0
21	1	50.0	0.0	50.0	0.0	100.0	0.0
22	23	50.0	0.0	50.0	0.0	0.0	100.0
23	7	50.0	0.0	50.0	50.0	50.0	0.0
24	34	50.0	0.0	50.0	50.0	0.0	50.0
25	55	50.0	0.0	50.0	0.0	50.0	50.0
26	45	0.0	50.0	50.0	100.0	0.0	0.0
27	37	0.0	50.0	50.0	0.0	100.0	0.0

28	2	0.0	50.0	50.0	0.0	0.0	100.0
29	30	0.0	50.0	50.0	50.0	50.0	0.0
30	54	0.0	50.0	50.0	50.0	0.0	50.0
31	58	0.0	50.0	50.0	0.0	50.0	50.0
32	16	33.3	33.3	33.3	33.3	33.3	33.3
33	5	100.0	0.0	0.0	33.3	33.3	33.3
34	56	0.0	100.0	0.0	33.3	33.3	33.3
35	24	0.0	0.0	100.0	33.3	33.3	33.3
36	6	50.0	50.0	0.0	33.3	33.3	33.3
37	28	50.0	0.0	50.0	33.3	33.3	33.3
38	29	0.0	50.0	50.0	33.3	33.3	33.3
39	31	33.3	33.3	33.3	100.0	0.0	0.0
40	38	33.3	33.3	33.3	0.0	100.0	0.0
41	26	33.3	33.3	33.3	0.0	0.0	100.0
42	14	33.3	33.3	33.3	50.0	50.0	0.0
43	33	33.3	33.3	33.3	50.0	0.0	50.0
44	42	33.3	33.3	33.3	0.0	50.0	50.0
45	52	100.0	0.0	0.0	100.0	0.0	0.0
46	36	100.0	0.0	0.0	0.0	100.0	0.0
47	53	100.0	0.0	0.0	0.0	0.0	100.0
48	59	100.0	0.0	0.0	50.0	50.0	0.0
49	13	100.0	0.0	0.0	50.0	0.0	50.0
50	22	66.7	16.7	16.7	66.7	16.7	16.7
51	12	66.7	16.7	16.7	16.7	66.7	16.7
52	17	66.7	16.7	16.7	16.7	16.7	66.7
53	4	16.7	66.7	16.7	66.7	16.7	16.7
54	50	16.7	66.7	16.7	16.7	66.7	16.7
55	21	0.0	0.0	100.0	0.0	0.0	100.0
56	10	0.0	0.0	100.0	100.0	0.0	0.0
57	46	0.0	0.0	100.0	0.0	100.0	0.0
58	9	0.0	0.0	100.0	50.0	0.0	50.0
59	49	0.0	0.0	100.0	0.0	50.0	50.0

## Resultados y discusión

En este trabajo se evaluaron dos diferentes matrices de encapsulado para dos sistemas activos (antioxidante y microorganismo), para obtener un alimento

funcional por liofilización. En la matriz I formada por IN, L y MX, se obtuvo un rendimiento de 93.7% cuando IN está presente en un 66.71%, como ocurre en el experimento 54 (66.7IN; 16.7L; 16.7MX) y 87.6% cuando la IN está al 100% como es el caso del experimento 49 (100IN; 0L; 0MX). La matriz II que contiene gomas Arábiga (A), Guar (G), y Xantana (X), muestra un mejor rendimiento, correspondiente al 88.08% cuando las gomas A; G, y X están presentes en la misma proporción, por ejemplo en el experimento 32 (33.3A; 33.3G; 33.3X). Los resultados con respecto al rendimiento contribuyen a una amplia gama de respuestas, por ejemplo: I) el mayor rendimiento se obtiene cuando el agente acarreador en la matriz I se utiliza IN cercano a 100 y de la matriz II en una relación igual de A; G; X., II) El menor rendimiento al utilizar MX a 100 y de la matriz II al utilizar G a 100, III) Como utilizar estos encapsulantes matriz I (IN; L; MX) y la matriz II (A; G; X).

La viabilidad de *B. clausii* se midió mediante el método de unidades formadoras de colonia por gramo (CFU/g)). Los experimentos del 1 al 59 presentaron una disminución a 9.3 a 9.9 log<sub>10</sub> CFU/g, en comparación con el control 11.30 log<sub>10</sub> CFU/g. p. ej. para el experimento 40, con una proporción de 33.3IN; 33.3L; 33.3MX, se determinó una viabilidad de 9.85 log<sub>10</sub> CFU/g. Sin embargo se observó la viabilidad más alta de *B. clausii*, 9.8 log<sub>10</sub> CFU/g cuando se utilizó lactosa cerca de la unidad, como ocurre en el experimento 34 (0IN; 100L; 0MX). Al combinar 50 L; 50 MX, la viabilidad de *B. clausii*, fue de 9.37 log<sub>10</sub> CFU/g, correspondiente al experimento 27 (0 IN; 50 L; 50 MX). En la matriz I cuando los agentes acarreadores están presentes en la misma proporción, como ocurre en el experimento 32 (33.3IN; 33.3L; 33.3MX), la viabilidad fue de 9.75 log<sub>10</sub> CFU/g. Los resultados demuestran que el usar más de un agente acarreador mejora la supervivencia de *B. clausii*. Cabe mencionar que todas las muestras presentadas en este diseño de experimentos de tres componentes Scheffe especial cúbico x especial cúbico, sobrepasan el valor mínimo en viabilidad de 6.0 log<sub>10</sub> UFC/g recomendado por la FAO/OMS (2002) para ser considerado probiótico. Para la matriz II se encontró la viabilidad más alta de *B. clausii* en dos condiciones, al utilizar la unidad de G y al emplear una mezcla de G y X, por ejemplo en el experimento 31 con una composición de 0 A; 50G; 50X y el experimento 3 (0A; 100G; 0X). Los resultados

obtenidos, permiten indicar que: I) La viabilidad más alta se obtienen cuando los agentes acarreadores utilizados en la matriz I son L y/o mezcla de IN, L y MX en una relación igual y en la matriz II al utilizar G cerca de la unidad y/o G y X en la misma proporción. II) La viabilidad más baja se observa al utilizar L y MX en proporciones iguales en la matriz I y X cercana a la unidad en la matriz II III) Qué combinación de los agentes acarreadores y gomas permite una mejor preservación de la viabilidad, IV) se obtuvo un alimento funcional ya que el valor mínimo de viabilidad 6.0 log<sub>10</sub> UFC/g recomendado por la FAO/OMS (2002) para ser considerado probiótico se determinó por arriba de este valor en todos los estándares de esta investigación.

Se determinó la capacidad antioxidante por la inhibición del radical 2,2 difenil-1-picrilhidrazil (DPPH) a concentraciones de 5, 10 y 30 µg/ml (muestra), para la matriz I formada por IN, L y MX. La mayor AA se determinó cuando el agente acarreador está cerca a la unidad de inulina y corresponde al experimento 33 (100IN; 0L; 0MX) presenta una AA de 56.05 a una concentración de 5 µg/ml, de 58.75 para 10 µg/ml y 84.35 con 30 µg/ml. Sin embargo, cuando la matriz está compuesta por 50 IN; 50 L, que corresponde al experimento 15 (50IN;50L;0MX), la AA fue de 52.88 (5 µg/ml); 57.95 (10 µg/ml) y 81.51 (30 µg/ml). Las muestras que presentaron menos AA fueron las que están cerca a la unidad de MX, con una actividad 38.58 a 5 µg/ml; 43.27 a 10µg/ml y 63.1 para 30µg/ml. Para la matriz II compuesta por G; X; A, en la concentración de 5, 10 y 30µg/ml los resultados más favorables se obtienen al utilizar las G y X en proporciones iguales y sin presencia de A, por ejemplo, para el experimento 49 (0 A; 50 G; 50 X). Sin embargo, al estar presente la A cerca a la unidad la AA es menor por ejemplo para el experimento 20 (100 A; 0 G; 0 X) que corresponde a una AA 48.36 (5 µg/ml); 52.06(10 µg/ml) y 81.93(30 µg/ml). Los resultados obtenidos permiten identificar: I) Qué combinación de los agentes acarreadores y gomas permite un mayor porcentaje de actividad antioxidante, II) La actividad antioxidante más alta se obtienen cuando el agente acarreador utilizado en la matriz I es la inulina y en la matriz II G y X en la misma proporción para las concentraciones de 5 y 10 µg/ml, III) La actividad antioxidante más baja se observa al utilizar únicamente maltodextrina en la matriz I y G cercana a la unidad en la

matriz II. Este último aporte científico coincide con resultados reportados por los investigadores

## Conclusiones

Se preparó un ingrediente funcional formado por *B. clausii* y quercetina para dos matrices: Matriz I formada por I; L; MX y la matriz II formada por A; G; X mediante un diseño de experimentos D-optimal. Con respecto al rendimiento, al utilizar los tres componentes en una proporción igual tanto para la matriz I como para la matriz II se obtuvo el mayor rendimiento (88.08%), para el experimento 32 (1/3 I; 1/3 L; 1/3 MX) y (1/3 A; 1/3 G; 1/3 X). Para la matriz I se observa la viabilidad más alta 9.8 log<sub>10</sub> CFU/g al usar lactosa cerca a la unidad, correspondiente al experimento 34 (0IN; 100L; 0MX). La AA más alta cuando se usa la inulina cerca a la unidad, correspondiente al experimento 33 (100IN; 0L; 0MX), presentando una AA de 56.05 a una concentración de 5 µg/ml, 8.75 a 10 µg/ml y 84.35 con 30 µg/ml. Para la matriz II se presentó la viabilidad más alta en dos casos, al usar G cerca de la unidad y al emplear mezclas de G y X. por ejemplo en el experimento 31 con 9.9 log<sub>10</sub> CFU/g (0 A; 50G; 50X) y el experimento 3 con 9.8 log<sub>10</sub> CFU/g (0A; 100G; 0X). La AA más alta se obtuvo al utilizar G y X en proporciones iguales, correspondiendo al experimento 49 (0 A; 50 G; 50 X). con AA de 54.85 a una concentración de 5 µg/ml, 55.44 a 10 µg/ml y 67.09 con 30 µg/ml. El sinergismo entre las dos matrices ocurre al usar la proporción más alta de I y G, correspondiendo al experimento 46, con un rendimiento de 86.5%, viabilidad de 9.52 log<sub>10</sub> UFC/g y una AA de 54.85 a una concentración de 5 µg/ml, 55.44 a 10 µg/ml y 67.09 con 30 µg/ml. Cabe mencionar que todas las muestras sobrepasan el valor mínimo en viabilidad de 6.0 log<sub>10</sub> UFC/g recomendado por la FAO/OMS (2002) para ser considerado probiótico y contribuyen a la ingesta diaria de 10-16 mg/día de quercetina y en el caso de las muestras con inulina, a la ingesta de 10-20 g/día de este carbohidrato para obtener beneficios a la salud y de 25-38g de fibra por día

## Bibliografía

- Addor, F. A. S. (2017). Antioxidants in dermatology. *Anais Brasileiros de Dermatologia*, 92(3), 356–362. <https://doi.org/10.1590/abd1806-4841.20175697>
- Brand-Williams, W., Cuvelier, M. E., & Berset, C. (1995). Use of a free radical method to evaluate antioxidant activity. *LWT - Food Science and Technology*, 28(1), 25–30. [https://doi.org/https://doi.org/10.1016/S0023-6438\(95\)80008-5](https://doi.org/10.1016/S0023-6438(95)80008-5)
- Caballero, B. L., Márquez, C. J., & Betancur, M. I. (2017). Efecto de la liofilización sobre las características físico-químicas del ají rocoto (*Capsicum pubescens* R&P) con o sin semilla. *Bioagro*, 29(3), 225–234.
- Ciriminna, R., Meneguzzo, F., Delisi, R., & Pagliaro, M. (2017). Olive Biophenols as New Antioxidant Additives in Food and Beverage. *ChemistrySelect*, 2(4), 1360–1365. <https://doi.org/10.1002/slct.201601900>
- Commission, J. F. C. A. (2007). *Codex alimentarius : cereals, pulses, legumes and vegetable proteins*. First edition. Rome : World Health Organization : Food and Agriculture Organization of the United Nations, 2007.  
<https://search.library.wisc.edu/catalog/9910070210502121>
- De Castro, J. A. A., Guno, M. J. V. R., & Perez, M. O. (2019). *Bacillus clausii* as adjunctive treatment for acute community-acquired diarrhea among Filipino children: A large-scale, multicenter, open-label study (CODDLE). *Tropical Diseases, Travel Medicine and Vaccines*, 5(1), 1–9.  
<https://doi.org/10.1186/s40794-019-0089-5>
- Jafarinia, M., Sadat Hosseini, M., Kasiri, N., Fazel, N., Fathi, F., Ganjalikhani Hakemi, M., & Eskandari, N. (2020). Quercetin with the potential effect on allergic diseases. *Allergy, Asthma and Clinical Immunology*, 16(1), 1–11.  
<https://doi.org/10.1186/s13223-020-00434-0>
- Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2020). Neuroprotective effects of quercetin in alzheimer's disease. *Biomolecules*, 10(1). <https://doi.org/10.3390/biom10010059>
- Marunaka, Y., Marunaka, R., Sun, H., Yamamoto, T., Kanamura, N., Inui, T., & Taruno, A. (2017). Actions of quercetin, a polyphenol, on blood pressure.

- Molecules*, 22(2), 5–8. <https://doi.org/10.3390/molecules22020209>
- Miles, A. A., Misra, S. S., & Irwin, J. O. (1938). The estimation of the bactericidal power of the blood. *The Journal of Hygiene*, 38(6), 732–749. <https://doi.org/10.1017/s002217240001158x>
- Muñoz-López, C., Urrea-García, G. R., Jiménez-Fernández, M., Rodríguez-Jiménes, G. del C., & Luna-Solano, G. (2018). Efecto de las condiciones de liofilización en propiedades físicoquímicas, contenido de pectina y capacidad de rehidratación de rodajas de ciruela (*Spondias purpurea* L.). *Agrociencia*, 52(1), 1–13.
- Paparo, L., Tripodi, L., Bruno, C., Pisapia, L., Damiano, C., Pastore, L., & Berni Canani, R. (2020). Protective action of *Bacillus clausii* probiotic strains in an in vitro model of Rotavirus infection. *Scientific Reports*, 10(1), 1–10. <https://doi.org/10.1038/s41598-020-69533-7>
- Plomer, M., Perez, M., & Greifenberg, D. M. (2020). Effect of *Bacillus clausii* Capsules in Reducing Adverse Effects Associated with *Helicobacter pylori* Eradication Therapy: A Randomized, Double-Blind, Controlled Trial. *Infectious Diseases and Therapy*, 9(4), 867–878. <https://doi.org/10.1007/s40121-020-00333-2>
- Reyes-Farias, M., & Carrasco-Pozo, C. (2019). The anti-cancer effect of quercetin: Molecular implications in cancer metabolism. *International Journal of Molecular Sciences*, 20(13), 1–19. <https://doi.org/10.3390/ijms20123177>
- Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019). Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nature Reviews Gastroenterology and Hepatology*, 16(10), 605–616. <https://doi.org/10.1038/s41575-019-0173-3>
- Sarao, L. K., & Arora, M. (2017). Probiotics, prebiotics, and microencapsulation: A review. *Critical Reviews in Food Science and Nutrition*, 57(2), 344–371. <https://doi.org/10.1080/10408398.2014.887055>
- Zuidam, N. J., & Nedović, V. A. (2010). Encapsulation technologies for active food ingredients and food processing. *Encapsulation Technologies for Active Food Ingredients and Food Processing*, May, 1–400. <https://doi.org/10.1007/978-1-4419-1008-0>

**Reseña del artículo: Evaluation of two active system encapsulants matrices  
with quercetin and *Bacillus clausii* for functional foods**

El artículo correspondiente a este trabajo fue enviado para su publicación a una revista científica indexada (ANEXO)

## ANEXO: MANUSCRITO ENVIADO

31/7/22, 15:13

Correo: HECTOR ALFONSO ENCISO HUERTA - Outlook

Confirm co-authorship of submission to Carbohydrate Polymers

em.carbpol.0.7cd6dd.1fd08c80@editorialmanager.com <em.carbpol.0.7cd6dd.1fd08c80@editorialmanager.com>  
en nombre de  
Carbohydrate Polymers <em@editorialmanager.com>

Vie 22/07/2022 22:20

Para: HECTOR ALFONSO ENCISO HUERTA <A171051@alumnos.uaslp.mx>

\*This is an automated message.\*

Journal: Carbohydrate Polymers

Title: Evaluation of two active system encapsulants matrices with quercetin and Bacillus clausii for functional foods

Corresponding Author: Dr. María Zenaida Saavedra Leos

Co-Authors: Héctor Alfonso Enciso-Huerta; Miguel Ángel Ruiz-Cabrera; Laura Araceli Lopez-Martinez; Raúl Gonzalez-Carcia; Fidel Martinez-Gutierrez

Manuscript Number:

Dear Héctor Alfonso Enciso-Huerta,

The corresponding author Dr. María Zenaida Saavedra Leos has listed you as a contributing author of the following submission via Elsevier's online submission system for Carbohydrate Polymers.

Submission Title: Evaluation of two active system encapsulants matrices with quercetin and Bacillus clausii for functional foods

Elsevier asks all authors to verify their co-authorship by confirming agreement to publish this article if it is accepted for publication.

Please read the following statement and confirm your agreement by clicking on this link: <https://www.editorialmanager.com/carbpol/l.asp?i=1496974&l=GBLH0804>

I irrevocably authorize and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf (or, if the article is to be published under a CC BY license, a non-exclusive publishing agreement), in the relevant form set out at [www.elsevier.com/copyright](http://www.elsevier.com/copyright); and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights (or for CC BY articles a non-exclusive license of rights) to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article if it is accepted for publication shall apply and that this agreement is subject to the governing law of the country in which the journal owner is located.

<https://outlook.office.com/mail/deeplink?Print>

1/2

If you did not co-author this submission, please contact the corresponding author directly at [zenaida.saavedra@uaslp.mx](mailto:zenaida.saavedra@uaslp.mx).

Thank you,  
Carbohydrate Polymers

More information and support

FAQ: What is copyright co-author verification?

[https://service.elsevier.com/app/answers/detail/a\\_id/28460/supporthub/publishing/](https://service.elsevier.com/app/answers/detail/a_id/28460/supporthub/publishing/)

You will find information relevant for you as an author on Elsevier's Author Hub: <https://www.elsevier.com/authors>

FAQ: How can I reset a forgotten password?

[https://service.elsevier.com/app/answers/detail/a\\_id/28452/supporthub/publishing/](https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/)

For further assistance, please visit our customer service site: <https://service.elsevier.com/app/home/supporthub/publishing/>

Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/carbpol/login.asp?a=r>). Please contact the publication office if you have any questions.

# Carbohydrate Polymers

## Evaluation of two active system encapsulants matrices with quercetin and *Bacillus clausii* for functional foods

--Manuscript Draft--

<b>Manuscript Number:</b>	
<b>Article Type:</b>	Research Paper
<b>Keywords:</b>	Active system, matrices quercetin <i>Bacillus clausii</i> functional foods
<b>Corresponding Author:</b>	María Zenaida Saavedra Leos, Ph Universiada Autonoma de San Luis Potosí Matehuala, San Luis Potosí MEXICO
<b>First Author:</b>	Héctor Alfonso Enciso-Huerta
<b>Order of Authors:</b>	Héctor Alfonso Enciso-Huerta Miguel Ángel Ruiz-Cabrera Laura Araceli Lopez-Martinez Raúl Gonzalez-Carcia Fidel Martinez-Gutierrez María Zenaida Saavedra Leos, Ph
<b>Abstract:</b>	Currently, the demand for functional foods has been increasing in the public interest to improve their life expectations and general health. Food matrices containing probiotic microorganisms and active compounds encapsulated into carrier agents are essential in this context. Encapsulation by the lyophilization method is widely used because oxidation reactions affecting physicochemical and nutritional food properties are usually avoided. Encapsulated functional ingredients such as quercetin and <i>Bacillus clausii</i> using two carrier agents' matrices performed in I [inulin (I); lactose (L) and maltodextrin (MX)] and II [(Arabic (A), Guar (G) and Xanthan (X) Rubbers)] are presented in this work. A D-optimal procedure involving 59 experiments was designed to evaluate each matrix's yield, viability, and antioxidant activity (AA). Matrix I (33.3 I; 33.3 L; 33.3 MX) and matrix II (33.3 A; 33.3 G; 33.3 X) exhibited the best yield.
<b>Suggested Reviewers:</b>	Roberto Berni Canani, Doctor 1, University of Naples Federico II berni@unina.it  Camelia Vizireanu, Doctor 2, Dunarea de Jos University of Galati Faculty of Medicine and Pharmacy camelia.vizireanu@ugal.ro  Saber Amiri, Doctor 3, Urmia University m.rezazadehbari@urmia.ac.ir

1

2       **Evaluation of two active system encapsulants matrices with quercetin and**  
3       ***Bacillus clausii* for functional lyophilized foods preparation**

4       Héctor Alfonso Enciso-Huerta<sup>1</sup>, Miguel Ángel Ruiz-Cabrera<sup>1</sup>, Laura Araceli Lopez-Martinez<sup>2</sup>, Raúl  
5       Gonzalez-Garcia<sup>1</sup>, Fidel Martinez-Gutierrez<sup>1</sup> and María Zenaida Saavedra-Leos<sup>3\*</sup>

6

7       <sup>1</sup> Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6,  
8       San Luis Potosí, S.L.P. C.P. 78210, México.

9       <sup>2</sup> Coordinación Académica Región Altiplano Oeste, Universidad Autónoma de San Luis Potosí, Salinas  
10      de Hidalgo S.L.P. C.P. 78600, México.

11      <sup>3</sup> Coordinación Académica Región Altiplano, Universidad Autónoma de San Luis Potosí, 11 Carretera  
12      Cedral Km, 5+600 Ejido San José de las Trojes Matehuala, S.L.P. C.P. 78700, México.

13      \* Corresponding Author. E-mail address: [zenaida.saavedra@uaslp.mx](mailto:zenaida.saavedra@uaslp.mx)

14      **Abstract**

15      Currently, the demand for functional foods has been increasing in the public interest to improve their life  
16      expectations and general health. Food matrices containing probiotic microorganisms and active  
17      compounds encapsulated into carrier agents are essential in this context. Encapsulation by the  
18      lyophilization method is widely used because oxidation reactions affecting physicochemical and  
19      nutritional food properties are usually avoided. Encapsulated functional ingredients such as quercetin  
20      and *Bacillus clausii* using two carrier agents' matrices performed in I [inulin (I); lactose (L) and  
21      maltodextrin (MX)] and II [(Arabic (A), Guar (G) and Xanthan (X) Rubbers)] are presented in this work. A  
22      D-optimal procedure involving 59 experiments was designed to evaluate each matrix's yield, viability, and  
23      antioxidant activity (AA). Matrix I (33.3 I; 33.3 L; 33.3 MX) and matrix II (33.3 A; 33.3 G; 33.3 X) exhibited  
24      the best yield.

25

26

27   Keywords: functional, food, Inulin, Lactose

28   **1. Introduction**

29   According to the Codex alimentarius ([Commission, 2007](#)), food is any processed, semi-processed, or  
30   raw non-processed substance intended for human consumption (CXS 1-1985) with nutritional support. In  
31   the last years, derived from the SARS-CoV-2 (COVID-19) worldwide pandemic, the World Health  
32   Organization (WHO) suggested consuming healthy and essential foods for immunologic system function  
33   to prevent and considerably reduce the probability of appearance of diseases such as obesity, diabetes,  
34   cardiac, and some cancer types. For the reasons above, food plays a significant role in disease  
35   prevention, impacting public health. A “functional food” (FF) is defined by the European Society for  
36   Clinical Nutrition and Metabolism (ESPEN) guide as an enriched food with ingredients, nutrients, or  
37   additional compounds to manifest specifically benefits to health. In the last decade, FF production has  
38   become an important biotechnology industry given the growing consumer interest in improving their life  
39   expectancy and healthy due to awareness-raising about the prevention of certain diseases such as  
40   diabetes, cancer, and Alzheimer's ([Sarao & Arora, 2017](#)). Commonly, antioxidants are compounds of FF,  
41   added alone or mixed with other compounds to allow synergism, i.e. vitamin C to regenerate vitamin E  
42   tocopheryl radical after its oxidation ([Addor, 2017](#)). Antioxidants are added, obtaining different benefits,  
43   such as suppressing lipidic oxidation, increasing products' shelf life, and reducing the free radical  
44   concentrations inside of organism, consequently improving consumers' healthy ([Ciriminna et al., 2017](#)).  
45   Quercetin is an antioxidant flavonoid found in apples, grapes, beans, broccoli, red onion, tomatoes,  
46   oilseeds, flowers, tea leaves, and Ginko Biloba. Between 10-16 mg is ingested daily, although the  
47   recommended concentration is 1g daily ([Khan et al., 2020](#)). Different quercetin mechanisms had been  
48   reported in various diseases, i.e., in allergic asthma, the compound showed the inhibition of MUC5AC  
49   gene expression in NCI-H292 cells, triggered nasal mucosa human being anti-secretory agent preventing

50 the mucosa secretion in epithelial cells while maintaining a normal ciliary movement ([Jafarinia et al., 2020](#)).  
51

52 [Marunaka et al. \(2017\)](#) demonstrated that oral quercetin ingests of 150-730 mg daily for four weeks had  
53 antihypertensive, reducing systolic and diastolic pressure in patients in the first stage of hypertension.  
54 On the other hand, patients with metabolic syndrome who had consumed 150 mg daily of quercetin for  
55 five weeks significantly reduced their systolic pressure. An in vitro study by [Reyes-Farias & Carrasco-](#)  
56 [Pozo. \(2019\)](#) showed that quercetin functions as an antiviral agent against HIV, inhibiting the integrase,  
57 protease, and inverse transcriptase enzymes reducing HIV replication significantly.

58 Probiotics are other compounds present in FF, and their use confers benefits to health through the  
59 production of biliary enzymes, organic acid, satiety hormones, and immune system modulation through  
60 the improvement of antibodies response, the competence of substrates against pathogenic organisms,  
61 and the interaction with the microbiota ([Sanders et al., 2019](#)). *Bacillus clausii* is an anaerobic bacterium,  
62 gram-positive, used as a probiotic capable of generating spores and intestinal colonizers ([Paparo et al., 2020](#)). *B. clausii* is also resistant to heat, gastric pH, and antibiotics and can tolerate alkaline conditions.  
63 Nevertheless, its optimal conditions are 40°C at the pH of 9,0 ([De Castro et al., 2019](#)). [De Castro et al.](#)  
64 ([2019](#)). reported using it for seven days to treat acute infant diarrhea by viral cause or associated with  
65 antibiotics, showing the reduction of disease time, gastrointestinal symptoms, and evacuation frequency.  
66 Recently, in 2020 ([Plomer et al., 2020](#)). used *B. clausii* to reduce the adverse effects of *Helicobacter*  
67 *pylori* treatment, generally treated by antibiotics causing nausea, inflammation, vomit, and diarrheas  
68 triggering treatment failure and bacterial resistance.

70 Microencapsulation techniques are used to conserve any active ingredient sought to be added to food  
71 to preserve the antioxidant activity and viability of probiotic products against heat, oxygen, and humidity  
72 ([Zuidam & Nedović, 2010](#)). Drying by aspersion and lyophilization are most employer techniques for  
73 probiotic foods' production. Lyophilization preserves not only the nutritional foods' qualities but also their  
74 aromas and flavors, permitting their rehydration after the process by the final product porosity ([Muñoz-](#)

75 [López et al., 2018](#)). The Lyophilization technique is widely used in the food industry because, unlike the  
76 heat drying process, it does not catalyze oxidation reactions that can affect the properties of  
77 physicochemical and nutritional food ([Caballero et al., 2017](#)). Lyophilization drying uses sublimation of  
78 water and can be used to encapsulate aromas, scents, drugs, and in general, any thermosensitive  
79 material. Taking into consideration the antioxidants and probiotics for health, this research was planted  
80 to obtain a functional ingredient containing *B. clausii* and quercetin microencapsulated by lyophilization.

81

## 82 **2. Materials and methods**

### 83 *2.1 Materials*

84 Commercial Maltodextrin (MX) extracted from maize starch was acquired from INGREDION Mexico  
85 (Guadalajara, Mexico). Dextrose (DE) equivalent of MX was 10; with a molecular weight of 1625 g/mol  
86 and polymerization grade (DP) of 2-16 glucose units. Inulin (IN) was purchase from INGREDION Mexico  
87 (Guadalajara, Mexico).  $\alpha$ -lactose monohydrate (L), (L $\alpha$ ·H<sub>2</sub>O, purity  $\geq$  99,9 %) purchased from Sigma-  
88 Aldrich Chemical Co., Methanol, (MeOH, purity  $\geq$  99,8) was obtained from J.T. Baker. Rubbers Arabic  
89 (A), Guar (G) and Xanthan (X) from INGREDION Mexico (Guadalajara, Mexico). *Bacillus* strain (*B.*  
90 *clausii*) in sinuberase solution was purchased from Sanofi-Aventis Mexico, S.A. de C.V. (Coyocan,  
91 Mexico City, Mexico). Quercetin 3-D-Galactose (purity  $\geq$  99%) was acquired from Química Farmacéutica  
92 Esteroidal S.A de C.V., (Tlahuac, Mexico City, Mexico). Trypticase Soy Agar was obtained from  
93 Dickinson de México S.A de C.V. (Mexico City, Mexico). And 2,2-diphenyl-1-picrilhidrazile (DPPH)  
94 analytical grade from Sigma–Aldrich Chemical Co.

### 95 *2.2 Lyophilizes preparation*

96 Based on the mix's experiments, was prepared 100 g of samples (p/p), 10 g of matrix I, performed with  
97 IN, L, and MX, and 1 g of Matrix II of rubbers containing: A, G, and X. Each mass fraction for matrix I and  
98 II were established according to the experimental design. The compounds of each matrix were passed

99 by a 1 mm sieve and added to 87 g of deionized water, followed by magnetic agitation at 35 °C for 5  
100 minutes.

101 1 g of quercetin and 1g of *B. clausii* solution for 100 g final volume of solution (p/p) was added. Samples  
102 were stored in darkness at -80 °C. The micro-encapsulation process was performed by sublimation in a  
103 lyophilizer (IIShinbiobase® Model TFD8501, Gyeonggi-do, South Korea) with a vacuum pressure of 5  
104 mTorr -65 °C for approximately 120 h.

105 *2.3 Determination of microbial viability*

106 The viability of *B. clausii* before and after the encapsulation process was determined, resuspending 1 g  
107 of the microparticles obtained in 9 ml of saline solution (NaCl, 0.9% w/v). To break microcapsules, the  
108 suspension was agitated for 10 minutes with a vortex and incubated in a water bath for 10 minutes at 50  
109 °C. The viable cells were analyzed according to the method described by [Miles et al. \(1938\)](#). Briefly,  
110 dilutions of  $1 \times 10^{-3}$  a  $1 \times 10^{-9}$  performed in saline solution were sown on trypticase soy agar and incubated  
111 at 35 °C for 24 h. The evaluation was performed in triplicate and reported in colony-forming units per  
112 gram (CFU/g), using equation 1:

113

114 
$$Viability = \left[ \frac{\text{Number of colonies in box} * \text{dilution factor}}{\text{mL of sample sown}} \right] \quad (1)$$

115

116 *2.4 Antioxidant activity (AA)*

117 Quercetin antioxidant capacity was determinate according to the method described by [Brand-Williams et](#)  
118 [al. \(1995\)](#). Briefly, 1.7 mL of alcoholic solution of DPPH (0,1 mmol DPPH/L) were mixed with 1,7 mL of  
119 microencapsulated suspension, where the concentration of the microencapsulated varied from 2.5, 5,  
120 and 15 µg/mL. The mixture was left to stand in darkness for 30 minutes, and the absorbance at 537 nm  
121 was measured using a spectrophotometer UV-Vis Evolution 220 (Thermo Scientific, Walthman, MA.  
122 USA). The sweep percentage was calculated using equation 2:

$$AA (\%DPPH) = \frac{A_0 - A_{30}}{A_0} \times 100 \quad (2)$$

124 Where  $A_o$  represent the absorbance of blank solution (DPPH mixture and ethanol without  
125 microencapsulates),  $A_{30}$  represent the absorbance of DPPH solution and ethanol with  
126 microencapsulates after 30 minutes. The sweep activity was determined by triplicate for each sample.

127 2.5 Design of experiments and statistical analysis

Two independent mixtures were tested: Matrix I consisted of inulin (IN), lactose (L), and maltodextrin (MX), while Matrix II consisted of rubbers Arabic (A), guar (G), and xanthan (X). The lower and upper levels of these variables were between 0 and 100 (wt %), and the sum of the components in each mixture was 100% for each trial. The response variables were yield (%),  $B_c$  ( $\text{Log}_{10}$  CFU/g), and Antioxidant activity (the DPPH at concentrations of 5, 10, and 30 ( $\mu\text{g}/\text{g}$ )). In this manner, a combined experimental design of two matrices for a model Special Cubic  $\times$  Special Cubic was selected to evaluate the effect of each factor over each response variable. Table 1 shows the resulting 59 trials performed at the laboratory in random order.

136 An analysis of variance (ANOVA), was performed for each response (yield, *Bc*, Antioxidant activity) using  
137 Design-Expert® Version 12 Software (trial version) at the significance level of 0.05. The analyzed Scheffe  
138 model, special cubic x special cubic, was written as Equation 3:

$$140 \quad Y = (\alpha_1 A + \alpha_2 B + \alpha_3 C + \alpha_4 AB + \alpha_5 AC + \alpha_6 BC + \alpha_7 ABC) \times (\kappa_1 D + \kappa_2 E + \kappa_3 F + \kappa_4 DE + \\ 141 \quad \kappa_5 DF + \kappa_6 EF + \kappa_7 DEF) \quad (3)$$

which is an expanded way that results in 49 adjustable parameters.

143 Table 1. Experimental design of two matrices for a model special cubic x special cubic.

		Matrix I			Matrix II			
No	Run	IN	L	MX	A	G	X	
1	44	100.0	0.0	0.0	0.0	50.0	50.0	
2	15	0.0	100.0	0.0	100.0	0.0	0.0	

3	51	0.0	100.0	0.0	0.0	100.0	0.0
4	3	0.0	100.0	0.0	0.0	0.0	100.0
5	20	0.0	100.0	0.0	50.0	50.0	0.0
6	57	0.0	100.0	0.0	50.0	0.0	50.0
7	48	0.0	100.0	0.0	0.0	50.0	50.0
8	32	0.0	0.0	100.0	100.0	0.0	0.0
9	35	0.0	0.0	100.0	0.0	100.0	0.0
10	41	0.0	0.0	100.0	0.0	0.0	100.0
11	11	0.0	0.0	100.0	50.0	50.0	0.0
12	18	0.0	0.0	100.0	50.0	0.0	50.0
13	39	0.0	0.0	100.0	0.0	50.0	50.0
14	25	50.0	50.0	0.0	100.0	0.0	0.0
15	43	50.0	50.0	0.0	0.0	100.0	0.0
16	47	50.0	50.0	0.0	0.0	0.0	100.0
17	8	50.0	50.0	0.0	50.0	50.0	0.0
18	40	50.0	50.0	0.0	50.0	0.0	50.0
19	27	50.0	50.0	0.0	0.0	50.0	50.0
20	19	50.0	0.0	50.0	100.0	0.0	0.0
21	1	50.0	0.0	50.0	0.0	100.0	0.0
22	23	50.0	0.0	50.0	0.0	0.0	100.0
23	7	50.0	0.0	50.0	50.0	50.0	0.0
24	34	50.0	0.0	50.0	50.0	0.0	50.0
25	55	50.0	0.0	50.0	0.0	50.0	50.0
26	45	0.0	50.0	50.0	100.0	0.0	0.0
27	37	0.0	50.0	50.0	0.0	100.0	0.0
28	2	0.0	50.0	50.0	0.0	0.0	100.0
29	30	0.0	50.0	50.0	50.0	50.0	0.0
30	54	0.0	50.0	50.0	50.0	0.0	50.0
31	58	0.0	50.0	50.0	0.0	50.0	50.0
32	16	33.3	33.3	33.3	33.3	33.3	33.3
33	5	100.0	0.0	0.0	33.3	33.3	33.3
34	56	0.0	100.0	0.0	33.3	33.3	33.3
35	24	0.0	0.0	100.0	33.3	33.3	33.3
36	6	50.0	50.0	0.0	33.3	33.3	33.3
37	28	50.0	0.0	50.0	33.3	33.3	33.3
38	29	0.0	50.0	50.0	33.3	33.3	33.3
39	31	33.3	33.3	33.3	100.0	0.0	0.0
40	38	33.3	33.3	33.3	0.0	100.0	0.0
41	26	33.3	33.3	33.3	0.0	0.0	100.0
42	14	33.3	33.3	33.3	50.0	50.0	0.0
43	33	33.3	33.3	33.3	50.0	0.0	50.0
44	42	33.3	33.3	33.3	0.0	50.0	50.0

45	52	100.0	0.0	0.0	100.0	0.0	0.0
46	36	100.0	0.0	0.0	0.0	100.0	0.0
47	53	100.0	0.0	0.0	0.0	0.0	100.0
48	59	100.0	0.0	0.0	50.0	50.0	0.0
49	13	100.0	0.0	0.0	50.0	0.0	50.0
50	22	66.7	16.7	16.7	66.7	16.7	16.7
51	12	66.7	16.7	16.7	16.7	66.7	16.7
52	17	66.7	16.7	16.7	16.7	16.7	66.7
53	4	16.7	66.7	16.7	66.7	16.7	16.7
54	50	16.7	66.7	16.7	16.7	66.7	16.7
55	21	0.0	0.0	100.0	0.0	0.0	100.0
56	10	0.0	0.0	100.0	100.0	0.0	0.0
57	46	0.0	0.0	100.0	0.0	100.0	0.0
58	9	0.0	0.0	100.0	50.0	0.0	50.0
59	49	0.0	0.0	100.0	0.0	50.0	50.0

144

145

146

147 **3. Results and discussion**


148 *3.1 Microencapsulation performance*

149 The microencapsulation technique comprises the coating of small particles to form capsules with unique  
 150 properties and different morphologies, which can reach diameters between nanometres to millimeters,  
 151 protect bioactive ingredients against adverse reactions, and improve their functionality and bioavailability.  
 152 ([Zambrano et al., 2019](#)). Lyophilization is a microencapsulation process comprising the product's  
 153 previous freezing (-40°C) to be lyophilized, to after ice to sublime at sub-atmospheric pressures.

154 This work evaluated two different encapsulating matrices for two actives systems (antioxidant and  
 155 microorganism) to get functional lyophilized food. Matrix I containing IN, L and MX, as shown in Figure  
 156 1a, an efficiency of 93.7% when IN is present at 66.71%, for example experiment 54 (66.7IN; 16.7L;  
 157 16.7MX) and 87.6% for IN at 100% as is the case for experiment 49 (100IN; 0L; 0MX). Matrix II,  
 158 containing Arabic (A), Guar (G), and Xanthan (X) rubbers, shows better efficiency, corresponding to  
 159 88.08% when A; G, and X rubbers are present in the same proportion, e. g. the 32 experiment (33.3A;

160 33.3G; 33.3X), as shown in figure 1b. These results are consistent with ([Enache et al. \(2020\)](#) they  
161 employed to dry lyophilisation method to blackcurrant (*Ribes nigrum*) extract anthocyanins and  
162 encapsulate with bacteria (*Akkermansia muciniphila* and *Lactobacillus plantarum*) micro-encapsulate  
163 efficiency employing inulin and chitosan as carrier agent, reporting  $95.46\% \pm 1.30\%$  and  $87.38\% \pm 0.48\%$   
164 efficiency, respectively. ([Pudziuvelyte et al. \(2020\)](#), reported the ethanolic extract of *Elsholtzia ciliata*,  
165 microencapsulate lyophilisation yield with 6 carrier agents at 20% concentration and its mixes at 10%  
166 concentration: they employed Arabic rubbers (GUM\_E), maltodextrin (MALTO\_E), resistant maltodextrin  
167 (RES\_E), skimmed milk (SKIM\_E), sodium caseinate (SOD\_CAS\_E), beta-cyclodextrin  
168 (BETA\_CYCL\_E), the authors indicated that higher yield was observable when they employed SKIM\_E  
169 and MALTO\_E showed 100% and 95% efficiency, respectively, for mixtures of their observed 100% yield  
170 under two situations, use SKIM\_E;MALTO\_E and GUM\_E; BETA\_CYCL\_E. ([Sharifi et al. \(2021\)](#)  
171 performed co-microencapsulate *Lactobacillus Plantarum* and phytosterols mixtures formed by  $\beta$ -  
172 sitosterol (49.54%), campesterol (26.12%), stigmasterol (19.1%), Brassicasterol (1.48%). Researchers  
173 used Arabic rubber (GA), 2.25% w/v, and whey protein isolate (WPI), 5% w/v encapsulating agents. They  
174 formed coacervate followed by two dry process techniques: aspersion dry and lyophilization, obtaining  
175  $58.62 \pm 2.01\%$  and  $65.23 \pm 0.51\%$  yield, respectively. These results demonstrate improved performance  
176 when using a dry freeze-drying process. The yield results contribute to a range of responses, for example:  
177 (i) higher yields are obtained when the carrier agent used in matrix I is IN closer to 100, for matrix II the  
178 A; G; X in the same ratio, (ii) lower yields when using only MX at 100, in the case of matrix II when using  
179 G 100.

180



**Figure 1.** Yield surface graphic. (a) matrix I IN;L;MX, (b) Matrix II A; G; X

182 3.2. Viability of *B. clausii* microencapsulated

183 The viability of *B. clausii* was measured by the method Colony Forming Unit (CFU/g). The results shown  
184 in figure 2a were determined concerning the viability in matrix I. Experiments 1 to 59 had viability  
185 diminution at 9.3 to 9.9 log<sub>10</sub> CFU/g rate against control 11.30 log<sub>10</sub> CFU/g. E.g., For experiment 40,  
186 with the proportion of 33.3IN; 33.3L; 33.3MX, a viability value of 9.85 log<sub>10</sub> CFU/g was determined.  
187 Notwithstanding, we observed the higher viability of *B. clausii* 9.8 log<sub>10</sub> CFU/g when we used L closer to  
188 the unit, as experiment 34 shows (0IN; 100L; 0MX). Using a 50 L; 50 MX ratio, *B. clausii* viability was  
189 9.37 log<sub>10</sub> CFU/g, corresponding to experiment 27 (0 IN; 50 L; 50 MX). In matrix I, when the carrier  
190 agents were present in the same proportion, matching with experiment 32 (33.3IN; 33.3L; 33.3MX the  
191 viability was 9.75 log<sub>10</sub> CFU/g. Results show that using more than encapsulating agent improves the *B.*  
192 *clausii* survivance. It is worth mentioning that the standards presented in these experimental designs,  
193 particular three components Scheffe Special cubic x Special cubic, overpass the 6.0 log<sub>10</sub> CFU/g  
194 minimum value recommended by FAO/OMS (2002) to be considered probiotic and correlated with  
195 previous reports as [Enache et al. \(2020\)](#), who performed the co-microencapsulate *Lactobacillus casei*  
196 and the blackcurrant (*Ribes nigrum*) extract anthocyanin dried by lyophilization. They employed whey  
197 protein isolate (WPI), chitosan, and inulin at a 2:1:1 rate as carrier agents. The authors reported that the  
198 viability powder was 11 log<sub>10</sub> UFC/g as started value, after storage for 90 days at 4 °C it reduced to 8.13-  
199 6.35 log<sub>10</sub> UFC/g. Showing the stability of carrier agents' mixtures, [Milea et al. \(2020\)](#), reported the  
200 viability of co-microencapsulate via flavonoids lyophilization, got of yellow onion peelings (*Allium cepa*)  
201 and *Lactobacillus casei* employing whey protein isolate (WPI), inulin (I), and maltodextrin (MD) as carrier  
202 agents (2:1:1 proportion). The got encapsulated by lyophilization at 1% and, 2% concentrations were  
203 probed into food one (cream cheese). They reported results after storage of 21 days at 4 °C, showing a  
204 6.6 and 7.41 log<sub>10</sub> UFC/g viability at concentrations mentioned above. [Cayra et al. \(2017\)](#) suggest  
205 protection provided by L, IN, and MX materials to cellular structures of microorganisms by the formation  
206 of crystals and water molecules replacement at the polar groups of cellular membrane lipids. For the

207 Matrix II, we find the higher *B. clausii* viability value in two conditions, to use the unit of G and to employ  
208 a G and X mixture. E.g., the 31 experiment with 0 A; 50G; 50X composition and the 3 experiment (0A;  
209 100G; 0X). Got results showed I) higher viability was obtained when I and L were employed as a carrier  
210 agent in the matrix I and/or IN, L and MX at the same proportion, by the matrix II to use G closer to the  
211 unit and/or G and X at the same ratio. II) Lower viability was observed to use L and MX at the same rate  
212 in matrix I, and X closer to the unit in the matrix II. III) The better combination of carrier agents and rubbers  
213 that allows a better viability preservation. IV) We obtained one functional food, since the viability minimum  
214 value 6.0 log<sub>10</sub> CFU/g recommended by the FAO/OMS (2002) to be considerate as probiotic was  
215 determined over cross the value in all experiment of this research.

216

217

218

219

220

221

222

223

224

225

226

227

228


229

230

231

232

233






Figure 2. Graphics of surface responses to *B. clausii* viability dried by lyophilization expressed at  $\log_{10}$  (CFU/g). (a) Matrix I IN; L; MX, (b) Matrix II A; G; X.

234

235 *3.3. Antioxidant capacity determination*

236 Antioxidant capacity was determined by 2,2 diphenyl-1-picrilhidrazil (DPPH) radical inhibition using 5,10  
 237 and 30  $\mu\text{g}/\text{ml}$  (sample) as concentrations, as can be observed in figures 3 a), b) and c) the matrix I formed  
 238 by IN, L and MX, higher antioxidant activity (AA) was determinate when the carrier agent is closer to inulin  
 239 the unit and correspond to the 33 experiment (100IN; 0L; 0MX) presenting a 56.06 AA to 5  $\mu\text{g}/\text{ml}$   
 240 concentration, 58.75 to 10  $\mu\text{g}/\text{ml}$ , and 84.35 with 30  $\mu\text{g}/\text{ml}$ . Nevertheless, when the matrix is compound  
 241 by 50 IN; 50 L, corresponding to the 15 experiment (50IN;50L;0MX) AA was 52.88 (5  $\mu\text{g}/\text{ml}$ ); 57.95 (10  
 242  $\mu\text{g}/\text{ml}$ ) and 81.51 (30  $\mu\text{g}/\text{ml}$ ). Samples that presented less AA were those that were closer to the MX unit,  
 243 as shown in figures 3a;b;c; with an activity of 38.58 at 5  $\mu\text{g}/\text{ml}$ ; 43.27 at 10  $\mu\text{g}/\text{ml}$  y 63.1 to 30 $\mu\text{g}/\text{ml}$ .  
 244 These results correlate with observations reported by other authors such as [Martins et al. \(2021\)](#), who  
 245 performed a lemongrass (*Cymbopogon citratus* DC. Stapf) essential oil micro-encapsulation study, the  
 246 object of this work was to evaluate development, characterization and produced particle antioxidant

247 potential. Generated three different formulations for essential oil encapsulate, called M1 (5% of essential  
248 oil), M2 (10% of essential oil) and M3 (15% of essential oil), each mixture used maltodextrin MD (DE 20)  
249 and gelatine (GEL) at 4:1 (w/w) ratio as encapsulates agents. Result emulsions were lyophilized under  
250 0.011 mbar and -60 °C conditions for 48 h. Concerning antioxidant activity, authors reported in general  
251 way variety of the presence of bioactive compounds, functional groups and polarities such as part of  
252 essential oil, the lemongrass essential oil antioxidant effect had a start value of antioxidant capacity of  
253  $22.16 \pm 0.04$  mg TE/g measured by the DPPH method, after their lyophilization, samples presented as the  
254 antioxidant potential for M1  $2.46 \pm 0.12$  mg TE/g, M2  $7.74 \pm 0.05$  mg TE/g and M3  $12.10 \pm 0.30$  mg TE/g.  
255 Results showed that the MD (DE 20) use influences the antioxidant capacity. [Azarpazhooh et al. \(2019\)](#),  
256 evaluated pomegranate (*Punica granatum L.*) grinds extracted by the DPPH method antioxidant capacity  
257 (RSA). The process consisted of the use of Maltodextrin (MDX) in three proportions 5, 10 and 15% as  
258 carrier agent, and calcium alginate at 0.1/ (w/w), at 1:5 proportion. Researchers reported lower inhibitory  
259 concentration (IC50) 0.56 mg/ml at MDX to 15% sample. Against the 0.86 mg/ml IC50 observed in MDX  
260 at a 5% sample, their results indicate the influence MDX concentration over RSA increase.  
261 Notwithstanding, the obtained results could have been influenced by anthocyanins and polyphenols  
262 presents in the sample.  
263 For matrix II consisting of G; X; A, we show the results in figures 4 a), b) and c) at the concentration of 5,  
264 10 and 30 µg/ml more favourable results were obtained using the G and X at the same proportions without  
265 A presence. E.g. for the 49 experiment (0 A; 50 G; 50 X). Notwithstanding, with A closer to the unit, AA  
266 is lower, e.g. for the 20 experiment (100 A; 0 G; 0 X) corresponds to AA of 48.36 (5 µg/ml); 52.06 (10  
267 µg/ml) and 81.93(30 µg/ml) as shown in table 1. [Mansour et al. \(2020\)](#), micro-encapsulated anthocyanins  
268 (AC) extracts obtained by lyophilization from raspberries (*Rubus idaeus L.*). Evaluating three different  
269 anthocyanins concentrations, 0.025%, 0.05% and 0.075%, two encapsulating agents, soy protein isolate  
270 (SPI) and Arabic rubber (GA) at 5% concentration w/v and SPI; GA at 2.5;2.5 % w/v concentration.

271 Antioxidant capacity observed for these compounds at 0.025% was 25% for SPI, 45% for GA and 35%  
272 for SPI+GA mixture.

273 [Rezende et al. \(2018\)](#). Elaborated on industrial waste and pulp of steelyard (*Malpighia emarginata* DC).  
274 micro-encapsulate. They employed Arabic rubber (GA) and maltodextrin (MD) mixture in the same  
275 proportion (1:1; w/w) as carrier agents. They contrasted the antioxidant activity through the DPPH method  
276 for the industrial waste and pulp of steelyard by the dry aspersion and lyophilisation process. Antioxidant  
277 activity after the samples encapsulation process was 129.16 µM TE/g for lyophilised samples and 155.24  
278 µM TE/g for the samples dried by aspersion. Obtained results allow to identify I) carrier agents  
279 combination and rubbers that allow the best antioxidant activity percentage, II) higher antioxidant activity  
280 was obtained when the carrier agent used in the matrix I is inulin, for matrix II G and X at the same  
281 proportion for the 5 y 10 µg/ml concentrations, III) lower antioxidant activity is observing to use only  
282 maltodextrin in the matrix I and G closer to the unit in the matrix II. The last evidence is in line with results  
283 reported by researchers.

284

285

286

287

288

289


290

291


292

293

294



b



295

296

297




Figure 3. Antioxidant capacity by the 2,2 difenil-1-picrilhidrazil (DPPH) radical inhibition **a**) 5 µg/ml, **b**) 10 µg/ml and **c**) 30 µg/ml (sample), for matrix I formed by IN, L and MX

298

299

300

301

302



303

304

305

306

307






Figure 4. Antioxidant capacity by the 2,2 difenil-1-picrilhidrazil (DPPH) radical inhibition **a)** 5 µg/ml, **b)** 10 µg/ml and **c)** 30 µg/ml (sample), for matrix II formed by A, G and X

#### 311 **4.Conclusion**

312 We prepared a functional ingredient formed by *B. clausii* and quercetin for two matrices: Matrix I formed  
 313 by I; L; MX and matrix II formed by A; G; X through experimental designs D-optimal. With yield regard,  
 314 using the three compounds with the same proportion for both matrices we obtained a higher value  
 315 (88.08%), for the 32 experiment (33.3I; 33.3 L; 33.3 MX) and (33.3 A; 33.3 G; 33.3 X). We observed for  
 316 matrix II, the higher viability 9.8 log<sub>10</sub> CFU/gto use L closer to the unit corresponding to the 34 experiment  
 317 (0IN; 100L; 0MX). We obtained higher AA when the inulin was used closer to the unit corresponding to  
 318 the 33 experiment (100IN; 0L; 0MX) presenting an AA of 56.05 at 5 µg/ml concentration, 8.75 to 10 µg/ml  
 319 y 84.35 with 30 µg/ml. For matrix II, it presented higher viability values in two cases, to use G closer to

320 the unit, and to employ a G and X mixture. E.g., in the 31 experiment 9.9 log<sub>10</sub> CFU/g (0 A; 50G; 50X)  
321 and the 3 experiment 9.8 log<sub>10</sub> CFU/g (0A; 100G; 0X). Higher AA was got to use G and X in equal  
322 proportions, corresponding to the 49 experiment (0 A; 50 G; 50 X). With AA of 54.85 to a concentration  
323 of 5 µg/ml, 55.44 to 10 µg/ml and 67.09 with 30 µg/ml. Synergism between two matrices occurs using  
324 the higher I and G proportion, corresponding to the 46 experiment, with yield 86.5%, viability of 9.52 log<sub>10</sub>  
325 CFU/g 9.52 log<sub>10</sub> UFC/g and AA of 54.85 at 5 µg/ml concentration, 55.44 to 10 µg/ml and 67.09 with 30  
326 µg/ml. It is worth mentioning all samples over cross minimum viability value of 6.0 log<sub>10</sub> CFU/g  
327 recommended by FAO/OMS (2002) to be probiotic and contribute to diary inulin ingest of 10-16 mg/day  
328 recommended of quercetin and in cases of samples with inulin, to ingest of 10-20 g/day of this  
329 carbohydrate to get benefits to health and 25-38g of dietetic fibre per day.

330 **Acknowledgments**

331 Héctor Alfonso Enciso-Huerta is grateful to the national council of science and technology (CONACYT)  
332 in Mexico for the financial support provided during his Studies through the scholarship No. 784106.

333

334 **References:**

- 335 Addor, F. A. S. (2017). Antioxidants in dermatology. *Anais Brasileiros de Dermatologia*, 92(3), 356–362.  
336 <https://doi.org/10.1590/abd1806-4841.20175697>
- 337 Azarpazhooh, E., Sharayei, P., Zomorodi, S., & Ramaswamy, H. S. (2019). Physicochemical and  
338 Phytochemical Characterization and Storage Stability of Freeze-dried Encapsulated Pomegranate  
339 Peel Anthocyanin and In Vitro Evaluation of Its Antioxidant Activity. *Food and Bioprocess  
Technology*, 12(2), 199–210. <https://doi.org/10.1007/s11947-018-2195-1>
- 340 Brand-Williams, W., Cuvelier, M. E., & Berset, C. (1995). Use of a free radical method to evaluate  
341 antioxidant activity. *LWT - Food Science and Technology*, 28(1), 25–30.  
342 [https://doi.org/https://doi.org/10.1016/S0023-6438\(95\)80008-5](https://doi.org/https://doi.org/10.1016/S0023-6438(95)80008-5)
- 343 Caballero, B. L., Márquez, C. J., & Betancur, M. I. (2017). Efecto de la liofilización sobre las




- 370 Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2020). Neuroprotective effects of  
371 quercetin in alzheimer's disease. *Biomolecules*, 10(1). <https://doi.org/10.3390/biom10010059>
- 372 Mansour, M., Salah, M., & Xu, X. (2020). Effect of microencapsulation using soy protein isolate and gum  
373 arabic as wall material on red raspberry anthocyanin stability, characterization, and simulated  
374 gastrointestinal conditions. *Ultrasonics Sonochemistry*, 63, 104927.  
375 <https://doi.org/10.1016/j.ulsonch.2019.104927>
- 376 Martins, W. da S., de Araújo, J. S. F., Feitosa, B. F., Oliveira, J. R., Kotzebue, L. R. V., Agostini, D. L. da  
377 S., de Oliveira, D. L. V., Mazzetto, S. E., Cavalcanti, M. T., & da Silva, A. L. (2021). Lemongrass  
378 (*Cymbopogon citratus* DC. Stapf) essential oil microparticles: Development, characterization, and  
379 antioxidant potential. *Food Chemistry*, 355(March).  
380 <https://doi.org/10.1016/j.foodchem.2021.129644>
- 381 Marunaka, Y., Marunaka, R., Sun, H., Yamamoto, T., Kanamura, N., Inui, T., & Taruno, A. (2017). Actions  
382 of quercetin, a polyphenol, on blood pressure. *Molecules*, 22(2), 5–8.  
383 <https://doi.org/10.3390/molecules22020209>
- 384 Milea, Ștefania A., Vasile, M. A., Crăciunescu, O., Prelipcean, A. M., Bahrim, G. E., Râpeanu, G.,  
385 Oancea, A., & Stănciuc, N. (2020). Co-microencapsulation of flavonoids from yellow onion skins  
386 and lactic acid bacteria lead to multifunctional ingredient for nutraceutical and pharmaceuticals  
387 applications. *Pharmaceutics*, 12(11), 1–13. <https://doi.org/10.3390/pharmaceutics12111053>
- 388 Miles, A. A., Misra, S. S., & Irwin, J. O. (1938). The estimation of the bactericidal power of the blood. *The  
389 Journal of Hygiene*, 38(6), 732–749. <https://doi.org/10.1017/s002217240001158x>
- 390 Muñoz-López, C., Urrea-García, G. R., Jiménez-Fernández, M., Rodríguez-Jiménes, G. del C., & Luna-  
391 Solano, G. (2018). Efecto de las condiciones de liofilización en propiedades fisicoquímicas,  
392 contenido de pectina y capacidad de rehidratación de rodajas de ciruela (*Spondias purpurea* L.).  
393 *Agrociencia*, 52(1), 1–13.
- 394 Paparo, L., Tripodi, L., Bruno, C., Pisapia, L., Damiano, C., Pastore, L., & Berni Canani, R. (2020).

- 395 Protective action of *Bacillus clausii* probiotic strains in an in vitro model of Rotavirus infection.
- 396 *Scientific Reports*, 10(1), 1–10. <https://doi.org/10.1038/s41598-020-69533-7>
- 397 Plomer, M., Perez, M., & Greifenberg, D. M. (2020). Effect of *Bacillus clausii* Capsules in Reducing
- 398 Adverse Effects Associated with *Helicobacter pylori* Eradication Therapy: A Randomized, Double-
- 399 Blind, Controlled Trial. *Infectious Diseases and Therapy*, 9(4), 867–878.
- 400 <https://doi.org/10.1007/s40121-020-00333-2>
- 401 Pudziuvelyte, L., Marksa, M., Sosnowska, K., Winnicka, K., Morkuniene, R., & Bernatoniene, J. (2020).
- 402 Freeze-drying technique for microencapsulation of *elsholtzia ciliata* Ethanolic extract using different
- 403 coating materials. *Molecules*, 25(9), 1–16. <https://doi.org/10.3390/molecules25092237>
- 404 Reyes-Farias, M., & Carrasco-Pozo, C. (2019). The anti-cancer effect of quercetin: Molecular implications
- 405 in cancer metabolism. *International Journal of Molecular Sciences*, 20(13), 1–19.
- 406 <https://doi.org/10.3390/ijms20123177>
- 407 Rezende, Y. R. R. S., Nogueira, J. P., & Narain, N. (2018). Microencapsulation of extracts of bioactive
- 408 compounds obtained from acerola (*Malpighia emarginata* DC) pulp and residue by spray and freeze
- 409 drying: Chemical, morphological and chemometric characterization. *Food Chemistry*, 254(January),
- 410 281–291. <https://doi.org/10.1016/j.foodchem.2018.02.026>
- 411 Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019). Probiotics and
- 412 prebiotics in intestinal health and disease: from biology to the clinic. *Nature Reviews*
- 413 *Gastroenterology and Hepatology*, 16(10), 605–616. <https://doi.org/10.1038/s41575-019-0173-3>
- 414 Sarao, L. K., & Arora, M. (2017). Probiotics, prebiotics, and microencapsulation: A review. *Critical*
- 415 *Reviews in Food Science and Nutrition*, 57(2), 344–371.
- 416 <https://doi.org/10.1080/10408398.2014.887055>
- 417 Sharifi, S., Rezazad-Bari, M., Alizadeh, M., Almasi, H., & Amiri, S. (2021). Use of whey protein isolate
- 418 and gum Arabic for the co-encapsulation of probiotic *Lactobacillus plantarum* and phytosterols by
- 419 complex coacervation: Enhanced viability of probiotic in Iranian white cheese. *Food Hydrocolloids*,

- 420 113, 106496. <https://doi.org/10.1016/j.foodhyd.2020.106496>
- 421 Zambrano, V., Bustos, R., & Mahn, A. (2019). Insights about stabilization of sulforaphane through
- 422 microencapsulation. *Helijon*, 5(11). <https://doi.org/10.1016/j.heliyon.2019.e02951>
- 423 Zuidam, N. J., & Nedović, V. A. (2010). Encapsulation technologies for active food ingredients and food
- 424 processing. *Encapsulation Technologies for Active Food Ingredients and Food Processing*, May,
- 425 1–400. <https://doi.org/10.1007/978-1-4419-1008-0>
- 426

# Graphical Abstract



22 July 2022

**Dr. Marcello Iacomini,  
Editor in Chief  
Carbohydrate Polymers**

We attached the original research article entitled "**Evaluation of two active system encapsulants matrices with quercetin and *Bacillus clausii* for functional lyophilized foods preparation**" which we would like to be considered for publication in the **Carbohydrate Polymers**. The present study contributes to currently, the demand for functional foods has been increasing in the public interest to improve their life expectations and general health. Food matrices containing probiotic microorganisms and active compounds encapsulated into carrier agents are essential in this context. Encapsulation by the lyophilization method is widely used because oxidation reactions affecting physicochemical and nutritional food properties are usually avoided. Encapsulated functional ingredients such as quercetin and *Bacillus clausii* using two carrier agents' matrices performed in I [inulin (I); lactose (L) and maltodextrin (MX)] and II [(Arabic (A), Guar (G) and Xanthan (X) Rubbers)] are presented in this work. A D-optimal procedure involving 59 experiments was designed to evaluate each matrix's yield, viability, and antioxidant activity (AA). Matrix I (33.3 I; 33.3 L; 33.3 MX) and matrix II (33.3 A; 33.3 G; 33.3 X) exhibited the best yield.

We confirm that

1. The article is original.
2. The article has been written by the stated authors who are ALL aware of its content and approve its submission.
3. The article has not been published previously
4. The article is not under consideration for publication elsewhere
5. No conflict of interest exists.
6. If accepted, the article will not be published elsewhere in the same form, in any language, without the written consent of the publisher.

Please address all correspondence concerning this manuscript to me at [zenaida.saavedra@uaslp.mx](mailto:zenaida.saavedra@uaslp.mx).

Thank you for considering this manuscript for the possible publication in your prestigious journal  
Sincerely,



**PhD. María Zenaida Saavedra Leos**  
**Full-time Professor**  
Coordinación Académica Región Altiplano.  
Universidad Autónoma de San Luis Potosí.  
Carretera Cedral Km. 5+600 Ejido San José de las Trojes  
Matehuala, S.L.P. C.P. 78700. México.